Traphaco Joint Stock Company (TRA) Fair Value & Analysis
Healthcare · VN · Market cap 3.3T VND
Fair value as of: Jun 24, 2026
Analysis
Traphaco Joint Stock Company (TRA) currently trades at 78,000 VND, while our model-based Fair Value estimate is 123,383 VND — implying the stock looks roughly 58.2% undervalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Traphaco Joint Stock Company, together with its subsidiaries, produces and trades in pharmaceutical products, chemicals, and medical supplies and equipment in Vietnam. The company offers medical supplies; antipyretics; medicines for the hair, eyes, central neutral system, respiratory system, and liver; and other products. It is also involved in the production of medicines to treat human diseases, nutritional food products, and medicines derived from medicinal herbs; trading in medicines, pharmaceuticals, vaccines-biological products, chemicals, and nutritional food products; planting of medicinal materials; and processing of medicinal herbs. Further, it plants and processes pharmaceutical materials, and agriculture and forestry products, as well as food supplements, cosmetics, and chemicals. The company was formerly known as Pharmaceutical and Medical Material and Equipments Joint Stock Company and changed its name to Traphaco Joint Stock Company in July 2001. Traphaco Joint Stock C…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Traphaco Joint Stock Company (TRA) undervalued?
What is the fair value of TRA?
What is the quality score of TRA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.